Freenome colorectal cancer test data improve on earlier results

Data ReadoutpositiveFreenome colorectal cancer testPositive

AI Analysis

Summary

Freenome's blood-based colorectal cancer screening test demonstrated improved results in a new study. Abbott, which has an agreement to market the test, could become the dominant player in the colorectal cancer screening market according to Evercore ISI analysts.

Outcome Details

New study results improved on earlier results for blood-based colorectal cancer screening test

Importance:6/10

Sentiment:

0.70

colorectal cancer screeningblood-based testdiagnosticpartnership

Related Companies

$ABT

Read the original article

Published by BioPharma Dive on July 13, 2026 6:35 PM

Read Original